omniture
来凯医药科技(上海)有限公司

Latest News

Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer

SHANGHAI and WARREN, N.J., May 23, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven, c...

2024-05-23 20:42 1820

Laekna Releases 2023 ESG Report

SHANGHAI and WARREN, N.J., April 29, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven,...

2024-04-29 20:30 1265

Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024

SHANGHAI and WARREN, N.J., April 7, 2024 /PRNewswire/ -- Laekna (2105.HK) announced that the compan...

2024-04-08 08:30 1237

Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024

* Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic ...

2024-01-04 12:40 1602

2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results

-     A multi-center phase Ib/III study in China and the United States led by ProfessorBinghe Xu, M...

2023-12-11 18:55 1367

Laekna, Inc. (2105.HK) Announces Interim Results 2023

* For the Phase II pivotal trial of Afuresertib (LAE002) + Paclitaxel for platinum-resistant recu...

2023-08-25 08:00 3478

Laekna announces first IND clearance by U.S. FDA for internally-discovered LAE102

SHANGHAI and WARREN, N.J. , May 21, 2023 /PRNewswire/ -- Laekna, a clinical-stage biotechnology com...

2023-05-21 22:23 2264

Laekna Announces First Patient Dosed in South Korea in LAE201INT2101 Phase 1/2 Study

SHANGHAI and WARREN, N.J., Sept. 6, 2022 /PRNewswire/ -- Laekna, a clinical-stage biotechnology com...

2022-09-06 17:02 1897

Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer

SHANGHAI and WARREN, N.J., May 26, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage biote...

2022-05-26 20:27 1653

Laekna Therapeutics Raises $61 Million in Series D financing

SHANGHAI and WARREN, N.J., May 18, 2022 /PRNewswire/ -- Laekna Therapeutics (" Laekna"), a clinical-...

2022-05-18 20:00 1972

Laekna Therapeutics Appoints Jeff Porter, Ph.D. as Chairman of Scientific Advisory Board

SHANGHAI and WARREN, N.J., March 29, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage glo...

2022-03-29 20:00 1445

Laekna Launched the new domain name www.laekna.com

SHANGHAI and WARREN, N.J., Feb. 6, 2022 /PRNewswire/ -- Laekna Group (Laekna Inc and all its direct...

2022-02-07 12:47 1508

Laekna Presents Vision and Strategy at NewYorkBIO/NYSE Emerging Company Showcase

SHANGHAI and WARREN, N.J., Dec. 24, 2021 /PRNewswire/ -- Laekna was invited by NewYorkBIO and the N...

2021-12-24 16:30 3694

Laekna Therapeutics reported positive results in two clinical studies for the treatment of various stages of prostate cancer at the ESMO Congress

SHANGHAI and WARREN, New Jersey, Sept. 16, 2021 /PRNewswire/ -- Laekna Therapeutics, an emerging in...

2021-09-16 17:06 1415

Laekna Therapeutics will present two clinical study results in ESMO 2021

SHANGHAI and WARREN, N.J., July 26, 2021 /PRNewswire/ -- Laekna Therapeutics, an emerging innovativ...

2021-07-26 13:26 2232